PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA

por Cerchione, C., Nappi, D., Pareto, A. E., Ronconi, S., Cangini, D., Ceccolini, M., Musuraca, G., Catalano, L., Martinelli, G.
Publicado 2022

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE

por Cerchione, C., Nappi, D., Pareto, A. E., Ronconi, S., Cangini, D., Ceccolini, M., Musuraca, G., Catalano, L., Martinelli, G.
Publicado 2022

PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET

por Cerchione, C., Nappi, D., Pareto, A. E., Ronconi, S., Cangini, D., Ceccolini, M., Musuraca, G., Catalano, L., Martinelli, G.
Publicado 2022

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT

por Cerchione, C., Nappi, D., Pareto, A. E., Ronconi, S., Cangini, D., Ceccolini, M., Musuraca, G., Catalano, L., Martinelli, G.
Publicado 2022